" class="no-js "lang="en-US"> Michael Corley, BSAC, on Partnerships in the Antibiotic Community
Monday, June 05, 2023

Breaking News

Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement of CyPep-1, a First-in-class Targeted Tumor Membrane Immunotherapy FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research

May 12 2023

Michael Corley, BSAC, on Partnerships Within the Antibiotic Community

In the video, Michael Corley, the Head of Policy & Public Affairs at the British Society for Antimicrobial Chemotherapy (BSAC), discusses the importance of partnerships within the antibiotic community.

Corley notes that partnerships between different organizations, including academia, industry, and government, are crucial for addressing the growing problem of antibiotic resistance. He highlights the need for collaboration in all stages of the drug development process, from basic research to clinical trials to regulatory approval.

Corley goes on to discuss some of the initiatives that BSAC is involved in to promote partnerships within the antibiotic community, including the development of guidelines for antibiotic prescribing and the creation of educational resources for healthcare professionals. He also emphasizes the importance of public engagement and awareness-raising in addressing the issue of antibiotic resistance.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

    News

     Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

    Appointments

     Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia

    Diseases

     Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

    Drug Development

     Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

    Drug Development

     Read more
More On